The therapeutic potential of induced hepatocyte-like cells generated by direct reprogramming on hepatic fibrosis.


Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, South Korea. [Email]


Until now, there is no effective anti-fibrotic therapy available for liver cirrhosis. Stem cell therapies have been studied for the treatment of hepatic fibrosis. However, the use of embryonic stem cells or induced pluripotent stem cells (iPSC) has limitations such as ethical concern or malignancy potential. Induced hepatocyte-like cells (iHEPs) generated by direct reprogramming technology may overcome these limitations.


Animal models,CCl4,Cell and tissue-based therapy,Direct reprogramming,Disease modeling,Hepatic disorders,Hepatic fibrosis,Hepatic stem cells,Induced pluripotent stem cells,Liver regeneration,Small molecule based reprogramming,Stem cell therapy,Stem cell transplantation,